Aribio to Participate in BIX 2025... Presentation on Oral Alzheimer's Treatment Development Process

Aribio announced on October 13 that it will participate in 'BIOPLUS-INTERPHEX KOREA 2025' (hereafter BIX 2025). The event will take place from October 15 to 17 at COEX in Seoul, where the company will present the progress of its innovative new drug development for AR1001.

BIX 2025 is the largest comprehensive bioindustry convention in Korea, organized by the Korea Biotechnology Industry Organization and supported by the Seoul Metropolitan Government and the Ministry of Trade, Industry and Energy. This year, a record 300 companies from 15 countries will participate. The event will feature a variety of programs-including exhibitions, conferences, partnering, and open innovation-to share the latest trends and innovative technologies in the global biohealth industry.

Aribio will introduce the innovation and development status of its oral Alzheimer's treatment, AR1001, during the 'Innovative New Drug Development On-site Session.' The session will also include discussions on innovation-driven research and development strategies and the future direction of next-generation bio new drug development. The session will be chaired by Dr. Bae Jingun, a leading authority in new drug development in Korea, and will feature research representatives from companies including Proteina and Genexine.

Fred Kim, Head of Aribio's US branch, will present on the discovery of new drug targets, candidate design, and development process for AR1001, which is currently undergoing global Phase 3 clinical trials in 13 countries. In particular, he will share detailed information and data on how Aribio has led the development of treatments for degenerative brain diseases and driven paradigm shifts in the global field, focusing on the key results from AR1001's Phase 2 clinical trials and patient treatment cases from the Phase 3 trials.

Kim stated, "Aribio has advanced the global Phase 3 clinical trials for AR1001 to a level comparable to major global pharmaceutical companies, reaching the final stages. As we approach commercialization, we hope this event will provide an opportunity to explore how our know-how and innovation in new drug development can translate into tangible results."

He added, "Through BIX 2025, we plan to share our experience with the largest global Phase 3 clinical trial currently underway in the Korean bio industry, as well as our science-based innovation strategies, to expand global partnerships."

Meanwhile, Aribio is in the process of merging with Kosdaq-listed company Solux, with the scheduled date set for January 20, 2026.

This content was produced with the assistance of AI translation services.